Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
暂无分享,去创建一个
Hermann Wätzig | Robert Minkner | H. Wätzig | Christin Scheller | Finja Krebs | Robert Minkner | Isabel Astner | Maria Gil‐Moles | Finja Krebs | I. Astner | María Gil-Moles | Christin Scheller | Maria Gil-Moles
[1] K. Subbarao,et al. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV , 2004, Journal of Virological Methods.
[2] Siqi Liu,et al. Identification of phosphorylation sites in the nucleocapsid protein (N protein) of SARS-coronavirus , 2007, International Journal of Mass Spectrometry.
[3] Peter Kuhn,et al. Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy , 2006, Journal of Virology.
[4] P. Roy,et al. Efficient assembly and release of SARS coronavirus‐like particles by a heterologous expression system , 2004, FEBS Letters.
[5] Shengqi Wang,et al. Subcellular localization and membrane association of SARS-CoV 3a protein , 2005, Virus Research.
[6] Ralph S. Baric,et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.
[7] Gili Kaufman,et al. Coronaviruses: Propagation, Quantification, Storage, and Construction of Recombinant Mouse Hepatitis Virus , 2011, Current protocols in microbiology.
[8] Hermann Wätzig,et al. Precise, fast and flexible determination of protein interactions by affinity capillary electrophoresis. Part 2: Cations , 2013, Electrophoresis.
[9] Dylan H. Morris,et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 , 2020, The New England journal of medicine.
[10] Samer I. Al-Gharabli,et al. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease , 2011, Antiviral Research.
[11] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[12] H. Doerr,et al. Stability and inactivation of SARS coronavirus , 2004, Medical Microbiology and Immunology.
[13] G. Kampf,et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents , 2020, Journal of Hospital Infection.
[14] G. Somsen,et al. One single, fast and robust capillary electrophoresis method for the direct quantification of intact adenovirus particles in upstream and downstream processing samples. , 2017, Talanta.
[15] I. Wilson,et al. A structural analysis of M protein in coronavirus assembly and morphology , 2010, Journal of Structural Biology.
[16] T. Graule,et al. Isoelectric points of viruses , 2009, Journal of applied microbiology.
[17] N. Petrovsky,et al. Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology , 2014, Journal of Virology.
[18] Lukasz P. Kozlowski,et al. Proteome-pI: proteome isoelectric point database , 2016, Nucleic Acids Res..
[19] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[20] P. Novák,et al. Protein Extraction and Precipitation , 2016 .
[21] H. Wätzig,et al. The lectin from the mushroom Pleurotus ostreatus: a phosphatase-activating protein that is closely associated with an alpha-galactosidase activity. A part of this paper has been presented as a preliminary report at the 17th Interlec. Meeting 1997 in Würzburg, Germany. , 2001, Plant science : an international journal of experimental plant biology.
[22] D. Barnard,et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV , 2011, Vaccine.
[23] Nobuhiro Fujii,et al. Inactivation of SARS Coronavirus by Means of Povidone-Iodine, Physical Conditions and Chemical Reagents , 2006, Dermatology.
[24] X. Mi,et al. Virus isoelectric point determination using single-particle chemical force microscopy. , 2019, Langmuir : the ACS journal of surfaces and colloids.
[25] L. Babiuk,et al. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines , 2005, Vaccine.
[26] G. Whittaker,et al. Role for Influenza Virus Envelope Cholesterol in Virus Entry and Infection , 2003, Journal of Virology.
[27] Lixia Chen,et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.
[28] Lun Song,et al. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV , 2020, Cellular & Molecular Immunology.
[29] R. Baric,et al. Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.
[30] Jiang Gu,et al. Progress and Prospects on Vaccine Development against SARS-CoV-2 , 2020, Vaccines.
[31] Characterization of rhinovirus subviral A particles via capillary electrophoresis, electron microscopy and gas phase electrophoretic mobility molecular analysis: Part II , 2013, Electrophoresis.
[32] H. Doerr,et al. SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation , 2005, Biologicals.
[33] E. Arriaga,et al. Recent advances in the analysis of biological particles by capillary electrophoresis , 2008, Electrophoresis.
[34] Yan Fu,et al. Low stability of nucleocapsid protein in SARS virus. , 2004, Biochemistry.
[35] H. Aydin,et al. Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: Insights into mechanisms of general viral fusion and inhibitor design , 2014, Protein science : a publication of the Protein Society.
[36] J. Ward,et al. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. , 2010, Viral immunology.
[37] G. Somsen,et al. Implementation of at‐line capillary zone electrophoresis for fast and reliable determination of adenovirus concentrations in vaccine manufacturing , 2019, Electrophoresis.
[38] A. D. Russell,et al. Antiseptics and Disinfectants: Activity, Action, and Resistance , 1999, Clinical Microbiology Reviews.
[39] G. Allmaier,et al. Characterization of rhinovirus subviral A particles via capillary electrophoresis, electron microscopy and gas‐phase electrophoretic mobility molecular analysis: Part I , 2012, Electrophoresis.
[40] Yoshimasa Tanaka,et al. Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China , 2020, International journal of biological sciences.
[41] Xiangxi Wang,et al. Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.
[42] J. Torres,et al. Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel , 2009, PLoS pathogens.
[43] Hermann Wätzig,et al. A comprehensive platform to investigate protein-metal ion interactions by affinity capillary electrophoresis. , 2015, Journal of pharmaceutical and biomedical analysis.
[44] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[45] Linqi Zhang,et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.
[46] Deborah R. Taylor,et al. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products , 2006, Transfusion.
[47] H. Nauwynck,et al. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges , 2012, Expert review of vaccines.
[48] Malik Peiris,et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.
[49] Y. Zhang,et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine , 2005, Vaccine.
[50] Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV‐2 , 2020, Protein science : a publication of the Protein Society.
[51] Ron D. Appel,et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..
[52] I. Wilson,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[53] S. Morikawa,et al. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[54] Krishna Shankara Narayanan,et al. Severe Acute Respiratory Syndrome Coronavirus 3a Protein Is Released in Membranous Structures from 3a Protein-Expressing Cells and Infected Cells , 2006, Journal of Virology.
[55] Hyeshik Chang,et al. The Architecture of SARS-CoV-2 Transcriptome , 2020, Cell.
[56] B. Fielding,et al. Coronavirus envelope protein: current knowledge , 2019, Virology Journal.
[57] S. Lo,et al. Thermal aggregation of SARS-CoV membrane protein , 2005, Journal of Virological Methods.
[58] Zacharias E. Andreadakis,et al. The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.
[59] N. Petrovsky,et al. Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant , 2015, Methods in molecular biology.
[60] L. Kremser,et al. Capillary electrophoresis of viruses, subviral particles and virus complexes. , 2007, Journal of separation science.
[61] Anton Andonov,et al. Architecture of the SARS coronavirus prefusion spike , 2006, Nature Structural &Molecular Biology.
[62] B. Neuman,et al. Purification of Coronavirus Virions for Cryo-EM and Proteomic Analysis , 2014, Methods in molecular biology.
[63] A. M. Leontovich,et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.
[64] Kaixian Chen,et al. Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction , 2005, The International Journal of Biochemistry & Cell Biology.
[65] Shailendra K. Saxena,et al. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV) , 2020, VirusDisease.
[66] P. Hotez,et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome , 2012, Expert review of vaccines.
[67] E. Park,et al. Characterization of human papillomavirus 6b L1 virus-like particles isolated from silkworms using capillary zone electrophoresis. , 2014, Journal of bioscience and bioengineering.
[68] Mubarak A. Alamri,et al. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants , 2020, Journal of Pharmaceutical Analysis.
[69] M. Frieman,et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.
[70] Jing Chen,et al. Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis. , 2003, Acta pharmacologica Sinica.
[71] R. L. Roper,et al. SARS vaccines: where are we? , 2009, Expert review of vaccines.
[72] F. Krammer,et al. SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.
[73] H. Doerr,et al. Efficacy of various disinfectants against SARS coronavirus , 2005, Journal of Hospital Infection.